阿立哌唑与利培酮治疗首发精神分裂症对照研究

A control study of aripiprazole vs risperidone in the treatment of first-episode schizophrenia

目的探讨阿立哌唑治疗首发精神分裂症的临床疗效及安全性。方法将60例首发精神分裂症患者随机分为两组各30例，研究组口服阿立哌唑治疗，对照组口服利培酮治疗，观察8周。于治疗前及治疗2周、4周、6周、8周末采用阳性与阴性症状评定量表及副反应量表评定临床疗效和不良反应。结果治疗8周末，研究组显效率76．7％、有效率93．3％；对照组分别为80．0％、93．3％，两组比较无显著性差异（P〉0．05）；两组阳性与阴性症状评定量表评分于治疗第2周末起均较治疗前有显著下降（P〈0．05或0．01），同期两组间比较均无显著性差异（P〉0．05）；两组不良反应均轻微，研究组主要表现为失眠、口干、恶心、头昏等；对照组主要表现为震颤、静坐不能、体质量增加、月经改变、血清泌乳素水平升高等。结论阿立哌唑治疗精神分裂症疗效显著且与利培酮相当、安全性高、依从性好。

Objective To explore the clinical efficacy and safety of aripiprazole vs risperidone in the treatment of first-episode schizophrenia. Methods Sixty first-episode schizophrenics were randomly assigned to two groups of 30 patients each, research group took orally aripiprazole and control group did risperidone for 8 weeks. Efficaeies were assessed with the Positive and Negative Syndrome Scale（PANSS） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before treatment and in the 2nd, 4th ,6th and 8th week. Results At the end of the 8th week, obvious effective and effective rates were 76. 7% and 93.3% in the research and 80.0% and 93.3% in the control group, respectively, which showed no significant differenees（P〉0.05） ; since the end of the 2nd week, the PANSS scores of both groups lowered more significantly compared with pretreatment（P〈0.05 or 0.01）, there were no significant differences in group comparisons（P〉0.05） ; adverse reactions of both groups were mild, those were mainly insomnia, dry mouth, nausea, dizziness and so on in the research and tremor, akathisia, weight gain, menstruation change, heightened prolactin level etc. in the control group. Conclusion Aripiprazole has an evident effect equivalent to risperidone, higher safety and better compliance in schizophrenia.